Aradigm Presents Phase 2 Data On Inhaled Liposomal Ciprofloxacin In Cystic Fibrosis At The North American Cystic Fibrosis Conference
Oct 27th 2008Drug InformationCystic Fibrosis
Aradigm Corporation (OTCBB: ARDM) it is presenting data from its Phase 2 study of inhaled liposomal ciprofloxacin (ARD-3100) in cystic fibrosis (CF) patients at the 22nd Annual North American Cystic Fibrosis (NACF) conference in Orlando, Florida. Completed in June 2008, the study was an open-label, two week efficacy and safety trial of once daily inhaled liposomal ciprofloxacin in 22 CF patients conducted at leading CF centers in Australia and New Zealand.
More: continued here
